Atezolizumab,Cabozantinib,tivozanib,nivolumab
Roche,Aveo Oncology,BMS
['atezo', 'renal,(-adrenal)', 'cabozantinib']
 #asco2023 highlights: no benefit to adding #atezolizumab to #cabozantinib in second line for advanced #renalcellcarcinoma. key points:
1 median pfs, os, and response rates were similar between cabozantinib 
Leader GU @InstitutoRoffo #GU #RCC #prostate #bladder #testis #GUcsm #clinicaltrials #Immunotherapy #PrecisionMedicine #OncoAlert #OncoReporte
Views Mine